Side-by-side comparison of AI visibility scores, market position, and capabilities
L-Nutra created the patented ProLon Fasting Mimicking Diet, backed by 25+ years of USC longevity research and 37 clinical studies; a 2024 Nature Communications study showed 2.5-year biological age reduction after 3 cycles.
L-Nutra is a nutri-technology company pioneering nutrition for longevity through evidence-based dietary programs and plant-based therapies. Founded by Dr. Valter Longo — director of the USC Longevity Institute and one of the world''s leading longevity scientists — L-Nutra commercializes decades of academic research into practical consumer and clinical nutrition products. Its flagship product, ProLon, is the world''s first patented Fasting Mimicking Diet (FMD): a 5-day proprietary nutrition program that provides carefully calibrated calories and macronutrients to trigger the cellular rejuvenation and metabolic benefits of fasting while allowing food consumption. ProLon is backed by 25+ years of scientific research, tested across 37 clinical studies, and protected by 134 global patents.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.